Skip to main content
Fig. 5 | Cancer Cell International

Fig. 5

From: Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction

Fig. 5

IT TransCon TLR7/8 Agonist potentiated activation of APCs and antigen-specific CD8 T cells in tumors. Mice were treated as described in Fig. 3. Dissociated tumor cells were isolated at various times following treatment and assessed for markers of immune-cell subsets and activation via flow cytometry. A Antigen presenting cell immunophenotyping following treatment initiation. *p < 0.05 vs Buffer on the same day, n = 5–11 per group per timepoint. B CD8 T cell granzyme B and PD-1 immunophenotyping on day 14 following treatment initiation. *p < 0.05 vs Buffer, n = 9–11/group. C %AH1-tetramer+ CD8 T cells on Day 14 following treatment initiation. n = 9–11/group

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us